Literature DB >> 7739538

Ligand-independent activation of the platelet-derived growth factor beta receptor: requirements for bovine papillomavirus E5-induced mitogenic signaling.

D Drummond-Barbosa1, R R Vaillancourt, A Kazlauskas, D DiMaio.   

Abstract

The E5 protein of bovine papillomavirus type 1 binds to and activates the endogenous platelet-derived growth factor (PDGF) beta receptor in fibroblasts, resulting in cell transformation. We have developed a functional assay to test the ability of PDGF beta receptor mutants to mediate a mitogenic signal initiated by the E5 protein. Lymphoid Ba/F3 cells are strictly dependent on interleukin-3 for growth, but coexpression of the wild-type PDGF beta receptor and the E5 or v-sis-encoded protein generated a mitogenic signal which allowed Ba/F3-derived cells to proliferate in the absence of interleukin-3. In these cells, the E5 protein bound to and caused increased tyrosine phosphorylation of both the mature and the precursor forms of the wild-type PDGF beta receptor. The tyrosine kinase activity of the receptor was necessary for E5-induced receptor tyrosine phosphorylation and mitogenic activity but not for complex formation with the E5 protein. In contrast, the PDGF-binding domain of the receptor was not required for complex formation with the E5 protein, E5-induced tyrosine phosphorylation or mitogenic activity, demonstrating that E5-mediated receptor activation is ligand independent. Analysis of receptor mutants lacking various combinations of tyrosine phosphorylation sites revealed that the E5 and v-sis-encoded proteins display similar requirements for signaling and suggested that the wild-type PDGF beta receptor can generate multiple independent mitogenic signals. Importantly, these mutants dissociated two activities of the PDGF beta receptor tyrosine kinase, both of which are required for sustained mitogenic signaling: (i) receptor autophosphorylation and creation of binding sites for SH2 domain-containing proteins and (ii) phosphorylation of substrates other than the receptor itself.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7739538      PMCID: PMC230487          DOI: 10.1128/MCB.15.5.2570

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  45 in total

1.  Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production.

Authors:  A D Miller; C Buttimore
Journal:  Mol Cell Biol       Date:  1986-08       Impact factor: 4.272

2.  Cellular transformation by a transmembrane peptide: structural requirements for the bovine papillomavirus E5 oncoprotein.

Authors:  A N Meyer; Y F Xu; M K Webster; A E Smith; D J Donoghue
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

3.  Direct interaction between Shc and the platelet-derived growth factor beta-receptor.

Authors:  K Yokote; S Mori; K Hansen; J McGlade; T Pawson; C H Heldin; L Claesson-Welsh
Journal:  J Biol Chem       Date:  1994-05-27       Impact factor: 5.157

4.  The bovine papillomavirus type 1 E5 transforming protein specifically binds and activates the beta-type receptor for the platelet-derived growth factor but not other related tyrosine kinase-containing receptors to induce cellular transformation.

Authors:  D J Goldstein; W Li; L M Wang; M A Heidaran; S Aaronson; R Shinn; R Schlegel; J H Pierce
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

5.  Activation of the SH2-containing phosphotyrosine phosphatase SH-PTP2 by its binding site, phosphotyrosine 1009, on the human platelet-derived growth factor receptor.

Authors:  R J Lechleider; S Sugimoto; A M Bennett; A S Kashishian; J A Cooper; S E Shoelson; C T Walsh; B G Neel
Journal:  J Biol Chem       Date:  1993-10-15       Impact factor: 5.157

6.  Demonstration that a chemically synthesized BPV1 oncoprotein and its C-terminal domain function to induce cellular DNA synthesis.

Authors:  M Green; P M Loewenstein
Journal:  Cell       Date:  1987-12-04       Impact factor: 41.582

7.  Tyr-716 in the platelet-derived growth factor beta-receptor kinase insert is involved in GRB2 binding and Ras activation.

Authors:  A K Arvidsson; E Rupp; E Nånberg; J Downward; L Rönnstrand; S Wennström; J Schlessinger; C H Heldin; L Claesson-Welsh
Journal:  Mol Cell Biol       Date:  1994-10       Impact factor: 4.272

8.  Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo.

Authors:  R Palacios; M Steinmetz
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

9.  Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice.

Authors:  P Soriano
Journal:  Genes Dev       Date:  1994-08-15       Impact factor: 11.361

10.  Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus.

Authors:  M D Waterfield; G T Scrace; N Whittle; P Stroobant; A Johnsson; A Wasteson; B Westermark; C H Heldin; J S Huang; T F Deuel
Journal:  Nature       Date:  1983 Jul 7-13       Impact factor: 49.962

View more
  32 in total

1.  Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.

Authors:  Jennifer L Rocnik; Rachel Okabe; Jin-Chen Yu; Benjamin H Lee; Neill Giese; David P Schenkein; D Gary Gilliland
Journal:  Blood       Date:  2006-04-20       Impact factor: 22.113

2.  Biologically active LIL proteins built with minimal chemical diversity.

Authors:  Erin N Heim; Jez L Marston; Ross S Federman; Anne P B Edwards; Alexander G Karabadzhak; Lisa M Petti; Donald M Engelman; Daniel DiMaio
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-10       Impact factor: 11.205

3.  Productive interaction between transmembrane mutants of the bovine papillomavirus E5 protein and the platelet-derived growth factor beta receptor.

Authors:  Char-Chang Lai; Anne P B Edwards; Daniel DiMaio
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

4.  A single amino acid substitution converts a transmembrane protein activator of the platelet-derived growth factor β receptor into an inhibitor.

Authors:  Lisa M Petti; Kristina Talbert-Slagle; Megan L Hochstrasser; Daniel DiMaio
Journal:  J Biol Chem       Date:  2013-08-01       Impact factor: 5.157

5.  Compensatory mutants of the bovine papillomavirus E5 protein and the platelet-derived growth factor β receptor reveal a complex direct transmembrane interaction.

Authors:  Anne P B Edwards; Yanhua Xie; Lara Bowers; Daniel DiMaio
Journal:  J Virol       Date:  2013-08-07       Impact factor: 5.103

6.  Artificial transmembrane oncoproteins smaller than the bovine papillomavirus E5 protein redefine sequence requirements for activation of the platelet-derived growth factor beta receptor.

Authors:  Kristina Talbert-Slagle; Sara Marlatt; Francisco N Barrera; Ekta Khurana; Joanne Oates; Mark Gerstein; Donald M Engelman; Ann M Dixon; Daniel Dimaio
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

7.  The canine papillomavirus e5 protein signals from the endoplasmic reticulum.

Authors:  Rachel Condjella; Xuefeng Liu; Frank Suprynowicz; Hang Yuan; Sawali Sudarshan; Yuhai Dai; Richard Schlegel
Journal:  J Virol       Date:  2009-10-07       Impact factor: 5.103

8.  Bovine papillomavirus E5 protein induces oligomerization and trans-phosphorylation of the platelet-derived growth factor beta receptor.

Authors:  C C Lai; C Henningson; D DiMaio
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

Review 9.  The bovine papillomavirus E5 protein and the PDGF beta receptor: it takes two to tango.

Authors:  Kristina Talbert-Slagle; Daniel DiMaio
Journal:  Virology       Date:  2008-11-06       Impact factor: 3.616

10.  E5 oncoprotein transmembrane mutants dissociate fibroblast transforming activity from 16-kilodalton protein binding and platelet-derived growth factor receptor binding and phosphorylation.

Authors:  J Sparkowski; M Mense; J Anders; R Schlegel
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.